COLLABORATIVE COMPARISON OF BROTH MACRODILUTION AND MICRODILUTION ANTIFUNGAL SUSCEPTIBILITY TESTS

被引:204
作者
ESPINELINGROFF, A
KISH, CW
KERKERING, TM
FROMTLING, RA
BARTIZAL, K
GALGIANI, JN
VILLAREAL, K
PFALLER, MA
GERARDEN, T
RINALDI, MG
FOTHERGILL, A
机构
[1] MERCK & CO INC, SCI & TECHNOL POLICY, RAHWAY, NJ 07065 USA
[2] MERCK RES LABS, RAHWAY, NJ 07065 USA
[3] VET AFFAIRS MED CTR, TUCSON, AZ 85723 USA
[4] UNIV ARIZONA, COLL MED, TUCSON, AZ 85723 USA
[5] UNIV IOWA, COLL MED, IOWA CITY, IA 52242 USA
[6] UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA
关键词
D O I
10.1128/JCM.30.12.3138-3145.1992
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A collaborative comparison of macro- and microdilution antifungal susceptibility tests was performed in five laboratories. MICs of amphotericin B, fluconazole, flucytosine, and ketoconazole were determined in all five centers against 95 coded isolates of Candida spp., Cryptococcus neoformans, and Torulopsis glabrata. A standard protocol with the following National Committee for Clinical Laboratory Standards Subcommittee on Antifungal Susceptibility Testing recommendations was used: an inoculum standardized by spectrophotometer, buffered (RPMI 1640) medium (pH 7.0), incubation at 35-degrees-C, and an additive drug dilution procedure. Two inoculum sizes were tested (1 X 10(4) to 5 x 10(4) and 0.5 x 10(3) to 2.5 x 10(3) CFU/ml) and three scoring criteria were evaluated for MIC endpoint determinations, which were scored as 0 (optically clear), less-than-or-equal-to 1 (slightly hazy turbidity), and less-than-or-equal-to 2 (prominent decrease in turbidity compared with that of the growth control). Overall intra- and interlaboratory reproducibility was optimal with the low-density inoculum, the second-day readings, and MICs scored as either 1 or 2. The microdilution MICs demonstrated interlaboratory agreement with most of the four drugs higher than or similar to that of the macrodilution MICs. In general, there was good interlaboratory agreement with amphotericin B, fluconazole, and flucytosine; ketoconazole gave more variable results.
引用
收藏
页码:3138 / 3145
页数:8
相关论文
共 31 条
[1]  
[Anonymous], 1985, MANUAL CLIN MICROBIO
[2]   CANDIDA-ALBICANS BIOTYPES IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1-INFECTED PATIENTS WITH ORAL CANDIDIASIS BEFORE AND AFTER ANTIFUNGAL THERAPY [J].
BRUATTO, M ;
VIDOTTO, V ;
MARINUZZI, G ;
RAITERI, R ;
SINICCO, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1991, 29 (04) :726-730
[3]   NEW FLUORESCENCE ASSAY FOR THE QUANTITATION OF FUNGI [J].
COLEMAN, T ;
MADASSERY, JV ;
KOBAYASHI, GS ;
NAHM, MH ;
LITTLE, JR .
JOURNAL OF CLINICAL MICROBIOLOGY, 1989, 27 (09) :2003-2007
[4]   INCIDENCE OF POLYENE-RESISTANT YEASTS RECOVERED FROM CLINICAL SPECIMENS [J].
DICK, JD ;
MERZ, WG ;
SARAL, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 18 (01) :158-163
[5]   EFFECT OF MEDIUM COMPOSITION ON RESULTS OF MACROBROTH DILUTION ANTIFUNGAL SUSCEPTIBILITY TESTING OF YEASTS [J].
DOERN, GV ;
TUBERT, TA ;
CHAPIN, K ;
RINALDI, MG .
JOURNAL OF CLINICAL MICROBIOLOGY, 1986, 24 (04) :507-511
[6]   STANDARDIZATION OF YEAST INOCULA WITH AN ELECTRONIC IMPEDANCE COUNTER [J].
ENG, C ;
VALENSTEIN, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1989, 27 (10) :2397-2399
[7]   COMPARISON STUDY OF BROTH MACRODILUTION AND MICRODILUTION ANTIFUNGAL SUSCEPTIBILITY TESTS [J].
ESPINELINGROFF, A ;
KERKERING, TM ;
GOLDSON, PR ;
SHADOMY, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 1991, 29 (06) :1089-1094
[8]   DEVELOPMENT OF RESISTANCE IN CANDIDA ISOLATES FROM PATIENTS RECEIVING PROLONGED ANTIFUNGAL THERAPY [J].
FANHAVARD, P ;
CAPANO, D ;
SMITH, SM ;
MANGIA, A ;
ENG, RHK .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (11) :2302-2305
[9]  
FROMTLING RA, UNPUB MULTICENTER EV
[10]  
GALGIANI JN, 1990, REV INFECT DIS, V12, pS272